

# Alessandro Passardi

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5793325/alessandro-passardi-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

93  
papers

2,375  
citations

22  
h-index

47  
g-index

114  
ext. papers

2,919  
ext. citations

4.8  
avg. IF

4.44  
L-index

#	Paper	IF	Citations
93	Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. <i>Lancet Oncology, The</i> , <b>2009</b> , 10, 943-9	21.7	443
92	Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. <i>Lancet Oncology, The</i> , <b>2005</b> , 6, 369-76	21.7	219
91	Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs. <i>Cancer Letters</i> , <b>2013</b> , 335, 225-31	9.9	190
90	Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1201-1207	10.3	103
89	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 497-507	21.7	98
88	Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 33210-9	3.3	98
87	A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. <i>Supportive Care in Cancer</i> , <b>2005</b> , 13, 888-94	3.9	86
86	Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	80
85	Immune Checkpoints as a Target for Colorectal Cancer Treatment. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	79
84	Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 3609-15	7.5	64
83	Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. <i>European Journal of Cancer</i> , <b>2017</b> , 86, 106-114	7.5	54
82	Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	44
81	KRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC). <i>PLoS ONE</i> , <b>2014</b> , 9, e92071	3.7	43
80	Shifts of Faecal Microbiota During Sporadic Colorectal Carcinogenesis. <i>Scientific Reports</i> , <b>2018</b> , 8, 10329	4.9	39
79	Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	31
78	Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study. <i>Journal of Translational Medicine</i> , <b>2012</b> , 10, 87	8.5	31
77	Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 46678-46691	3.3	30

76	Biomarkers and Molecular Imaging as Predictors of Response to Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer. <i>Clinical Colorectal Cancer</i> , <b>2015</b> , 14, 227-38	3.8	28
75	Gene methylation in rectal cancer: predictive marker of response to chemoradiotherapy?. <i>Journal of Cellular Physiology</i> , <b>2013</b> , 228, 2343-9	7	27
74	Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer. <i>PLoS ONE</i> , <b>2015</b> , 10, e0134732	3.7	25
73	eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial. <i>Journal of Translational Medicine</i> , <b>2015</b> , 13, 258	8.5	23
72	DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. <i>Pharmacogenomics Journal</i> , <b>2019</b> , 19, 556-563	3.5	20
71	TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. <i>BMC Cancer</i> , <b>2017</b> , 17, 408	4.8	20
70	Radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival. <i>OncoTargets and Therapy</i> , <b>2018</b> , 11, 6555-6567	4.4	20
69	Optimisation and validation of a remote monitoring system (Onco-Trec) for home-based management of oral anticancer therapies: an Italian multicentre feasibility study. <i>BMJ Open</i> , <b>2017</b> , 7, e014617	3	18
68	Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab. <i>Scientific Reports</i> , <b>2017</b> , 7, 1293	4.9	17
67	Role of p53 codon 72 arginine allele in cell survival in vitro and in the clinical outcome of patients with advanced breast cancer. <i>Tumor Biology</i> , <b>2008</b> , 29, 145-51	2.9	17
66	First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: The PANDA study.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4002-4002	2.2	16
65	TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable and wild-type metastatic colorectal cancer. <i>ESMO Open</i> , <b>2018</b> , 3, e000403	6	15
64	miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer. <i>OncoTargets and Therapy</i> , <b>2016</b> , 9, 2735-42	4.4	15
63	Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 129, 44-53	7	15
62	Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: results from the ITACa trial. <i>Oncotarget</i> , <b>2016</b> , 7, 10193-202	3.3	14
61	Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2017</b> , 79, 863-871	3.5	12
60	Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer. <i>European Radiology</i> , <b>2018</b> , 28, 2969-2978	8	12
59	Implementing an evidence-based computerized decision support system linked to electronic health records to improve care for cancer patients: the ONCO-CODES study protocol for a randomized controlled trial. <i>Implementation Science</i> , <b>2016</b> , 11, 153	8.4	12

58	Genomic alterations in rectal tumors and response to neoadjuvant chemoradiotherapy: an exploratory study. <i>Radiation Oncology</i> , <b>2011</b> , 6, 161	4.2	12
57	Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3508-3508	2.2	12
56	Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review. <i>Oncotarget</i> , <b>2017</b> , 8, 66699-66708	3.3	11
55	Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study. <i>Radiation Oncology</i> , <b>2018</b> , 13, 172	4.2	11
54	Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study. <i>Cancer Management and Research</i> , <b>2019</b> , 11, 4357-4369	3.6	10
53	Discrepancies between VEGF -1154 G>A polymorphism analysis performed in peripheral blood samples and FFPE tissue. <i>International Journal of Molecular Sciences</i> , <b>2014</b> , 15, 13333-43	6.3	10
52	Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience. <i>BMC Cancer</i> , <b>2006</b> , 6, 76	4.8	10
51	Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a single-center cohort study. <i>World Journal of Surgical Oncology</i> , <b>2019</b> , 17, 58	3.4	8
50	Phase I study of paclitaxel and uracil plus tegafur combination in patients with pretreated metastatic breast cancer: drug sequencing based on preclinical modelling studies. <i>Oncology</i> , <b>2007</b> , 72, 118-24	3.6	8
49	Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, e394-e401	3.8	7
48	Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study. <i>Cancers</i> , <b>2019</b> , 11,	6.6	7
47	Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial by GONO. <i>ESMO Open</i> , <b>2019</b> , 4, e21177	1	7
46	Preoperative Chemotherapy and Resection Margin Status in Colorectal Liver Metastasis Patients: A Propensity Score Matched Analysis. <i>American Surgeon</i> , <b>2019</b> , 85, 488-493	0.8	7
45	Prolonged Pemetrexed Infusion Plus Gemcitabine in Refractory Metastatic Colorectal Cancer: Preclinical Rationale and Phase II Study Results. <i>Oncologist</i> , <b>2017</b> , 22, 886-e79	5.7	6
44	The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. <i>BMC Cancer</i> , <b>2018</b> , 18, 98	4.8	6
43	Treatment trends in metastatic pancreatic cancer patients: Is it time to change?. <i>Digestive and Liver Disease</i> , <b>2011</b> , 43, 225-30	3.3	6
42	Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients. <i>Melanoma Research</i> , <b>2009</b> , 19, 100-5	3.3	6
41	An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?. <i>Anti-Cancer Drugs</i> , <b>2010</b> , 21, 459-64	2.4	6

40	Reversible, PET-positive, generalized lymphadenopathy and splenomegaly during high-dose interferon-alpha-2b adjuvant therapy for melanoma. <i>Journal of Immunotherapy</i> , <b>2008</b> , 31, 675-8	5	6
39	Post-traumatic stress symptoms in long-term disease-free cancer survivors and their family caregivers. <i>Cancer Medicine</i> , <b>2021</b> , 10, 3974-3985	4.8	6
38	IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab. <i>Cancer Management and Research</i> , <b>2018</b> , 10, 5659-5666	3.6	6
37	Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial. <i>Scientific Reports</i> , <b>2017</b> , 7, 10426	4.9	5
36	Hemangioblastoma of the gastrointestinal tract: a first case. <i>International Journal of Surgical Pathology</i> , <b>2013</b> , 21, 192-6	1.2	5
35	Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models. <i>Journal of Cellular and Molecular Medicine</i> , <b>2011</b> , 15, 316-26	5.6	5
34	Impact of second-line treatment (2L T) in advanced pancreatic cancer (APDAC) patients (pts) receiving first line Nab-Paclitaxel (nab-P) + Gemcitabine (G): An Italian multicentre real life experience.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4124-4124	2.2	5
33	Prognostic role of a new index (multi inflammatory index) in patients with metastatic colorectal cancer: results from the randomized ITACa trial. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920958363	5.4	5
32	Prognostic role of aspartate aminotransferase-lymphocyte ratio index in patients with metastatic colorectal cancer: results from the randomized ITACa trial. <i>OncoTargets and Therapy</i> , <b>2018</b> , 11, 5261-5268	4.4	5
31	Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications. <i>Journal of the National Cancer Institute</i> , <b>2021</b> ,	9.7	4
30	methylation and outcome of patients with advanced colorectal cancer treated with cetuximab. <i>Oncology Letters</i> , <b>2015</b> , 9, 1432-1438	2.6	3
29	Comprehensive analysis of DNA damage repair genes reveals pathogenic variants beyond BRCA and suggests the need for extensive genetic testing in pancreatic cancer. <i>BMC Cancer</i> , <b>2021</b> , 21, 611	4.8	3
28	Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study. <i>European Journal of Cancer</i> , <b>2021</b> , 155, 73-84	7.5	3
27	Intra-arterial chemotherapy of advanced pancreatic cancer: a single center experience. <i>Hepato-Gastroenterology</i> , <b>2007</b> , 54, 2373-7		3
26	Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer. <i>Journal of Translational Medicine</i> , <b>2008</b> , 6, 65	8.5	2
25	Nab-paclitaxel (Nab-P) and gemcitabine (G) first-line chemotherapy (CT) in patients (pts) with metastatic pancreatic cancer (mPC) who relapsed after adjuvant treatment (ADJ T): A REAL LIFE study.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 396-396	2.2	2
24	Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920937427	5.4	2
23	Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer. <i>Journal of Visualized Experiments</i> , <b>2019</b> ,	1.6	1

22	Instability of Non-Standard Microsatellites in Relation to Prognosis in Metastatic Colorectal Cancer Patients. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	1
21	Retrospective analysis of gastric cancer management in a real-world setting: a single-institution experience. <i>Tumori</i> , <b>2020</b> , 106, 165-171	1.7	1
20	Treatment of squamous cell carcinoma of the anal canal (SCCA): a new era?. <i>Annals of Oncology</i> , <b>2017</b> , 28, 2620	10.3	1
19	A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2010</b> , 65, 871-6	3.5	1
18	A phase Ib study of lapatinib plus pegylated liposomal doxorubicin in patients with advanced HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 600-600	2.2	1
17	Prognostic and predictive role of circulating eNOS and EPHB4 in metastatic colorectal cancer patients receiving bevacizumab.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e23083-e23083	2.2	1
16	Efficacy of bevacizumab in second-line versus first-line treatment of metastatic colorectal cancer: Results from a new methodological approach based on the ITACa strategy trial.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3546-3546	2.2	1
15	Medication reconciliation in cancer day hospital.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e17748-e17748	2.2	1
14	Prospective Observational Study Comparing Calcium and Sodium Levofolinate in Combination with 5-Fluorouracil in the FOLFIRI Regimen. <i>Oncologist</i> , <b>2021</b> , 26, e1314-e1319	5.7	1
13	Multimodal Treatment with GEMOX Plus Helical Tomotherapy in Unresectable Locally Advanced Pancreatic Cancer: A Pooled Analysis of Two Phase 2 Studies. <i>Biomolecules</i> , <b>2021</b> , 11,	5.9	1
12	Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. <i>European Journal of Cancer</i> , <b>2021</b> , 153, 16-26	7.5	1
11	A Remote Monitoring System to Optimize the Home Management of Oral Anticancer Therapies (ONCO-TreC): Prospective Training-Validation Trial.. <i>Journal of Medical Internet Research</i> , <b>2022</b> , 24, e27349	7.6	0
10	An Integrated Model to Improve Medication Reconciliation in Oncology: Prospective Interventional Study.. <i>Journal of Medical Internet Research</i> , <b>2021</b> , 23, e31321	7.6	0
9	Case Report: The Added Value of Liquid Biopsy in Advanced Colorectal Cancer From Clinical Case Experiences. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 745701	5.6	0
8	Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature.. <i>Cancer Treatment Reviews</i> , <b>2021</b> , 103, 102326	14.4	0
7	Neoadjuvant treatment (FOLFOX4 plus hypofractionated tomotherapy) for patients with locally advanced rectal cancer: a multicenter phase II trial. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920977139	5.4	0
6	Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial. <i>Pancreatology</i> , <b>2021</b> , 21, 1342-1348	3.8	0
5	Melanoma metastasis mimicking gastric cancer: a challenge that starts from diagnosis. <i>Therapeutic Advances in Gastroenterology</i> , <b>2021</b> , 14, 1756284821989559	4.7	0

4	FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies.. <i>European Journal of Cancer</i> , <b>2022</b> , 167, 23-31	7.5	o
3	Use of the ONCO-TreC electronic diary compared with a standard paper diary to improve adherence to oral cancer therapy in patients with solid and haematological tumours: protocol for a randomised controlled trial.. <i>BMJ Open</i> , <b>2022</b> , 12, e055814	3	
2	An easy-to-use nomogram to predict overall survival (OS) at 6 months after initiation of FOLFIRINOX first-line chemotherapy in patients (pts) with metastatic pancreatic cancer (mPC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 394-394	2.2	
1	Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma?.. <i>Medical Oncology</i> , <b>2021</b> , 38, 17	3.7	